Royalty Pharma (NASDAQ:RPRX – Get Free Report) and Revelation Biosciences (NASDAQ:REVB – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.
Profitability
This table compares Royalty Pharma and Revelation Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Royalty Pharma | 32.38% | 28.21% | 14.55% |
| Revelation Biosciences | N/A | -134.18% | -105.47% |
Earnings and Valuation
This table compares Royalty Pharma and Revelation Biosciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Royalty Pharma | $2.38 billion | 12.31 | $770.95 million | $1.35 | 37.60 |
| Revelation Biosciences | N/A | N/A | -$8.91 million | ($62.09) | -0.02 |
Royalty Pharma has higher revenue and earnings than Revelation Biosciences. Revelation Biosciences is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Royalty Pharma has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Revelation Biosciences has a beta of -0.14, meaning that its stock price is 114% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Royalty Pharma and Revelation Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Royalty Pharma | 0 | 0 | 6 | 0 | 3.00 |
| Revelation Biosciences | 1 | 0 | 0 | 0 | 1.00 |
Royalty Pharma presently has a consensus target price of $50.33, indicating a potential downside of 0.85%. Given Royalty Pharma’s stronger consensus rating and higher probable upside, equities analysts clearly believe Royalty Pharma is more favorable than Revelation Biosciences.
Institutional & Insider Ownership
54.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 8.0% of Revelation Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Royalty Pharma beats Revelation Biosciences on 13 of the 13 factors compared between the two stocks.
About Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
About Revelation Biosciences
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
